Sanofi fexinidazole approved by DRC for treatment of sleeping sickness

recently, FrenchPharmaceutical(http://giant Sanofi announced that fexinidazole has been approved by the Democratic Republic of the Congo (DRC) to treat the tripanos bruceomaiense human African trypanosomiasis, often referred to as "sleeping sickness."the approval, paving the way for the listing of fexinidazole in popular countriesSanofi has plans to submit a listing application for the drug in Ugandaabout fexinidazolefexinidazole was approved as a 10-day, once-a-daydrug(http://for the treatment of Burrows Gambiapite sleeping disease (the most common type of disease, found in West and Central Africa)fexinidazole is the first all-oral drug that applies both in the early stages of the disease and to the second stage of the disease where the parasite crosses the blood-brain barrier and causes neuropsychiatric symptoms in the patientAs a result, fexinidazole eliminates the patient's consistent hospital requirementsfexinidazole is a 5-nitromyzole derivative originally developed by Hoechst (Sanofi's predecessor) in the 1980s and later abandoned for strategic reasonsduring the search for compounds with anti-parasitic activity by the Neglected Disease Drug Development Organization (DNDi), which was identified in 2005 in cooperation with the Swiss Institute of Tropical and Public Healthin 2009, DNDi partnered with Sanofi, which owns theof the patented (http:// to restart research on the drug to treat sleeping sickness Among them, DNDi is responsible for preclinical, clinical and pharmaceutical development, and Sanofi is responsible for the industrial development, registration, production and sales of pharmaceutical (http://